How did Nu Skin's revenue and expenses trend in Q4 2024 compared to previous quarters?

Nu Skin's revenue and expenses in Q4 2024 showed a decline compared to the previous quarter, Q3 2024, but an increase year-over-year, Q4 2023.

1. Revenue Trend:
   • Nu Skin's revenue for Q4 2024 was $445.6 million.
   • This was a decrease from the previous quarter, Q3 2024, but an increase from the same quarter in the previous year, Q4 2023.
   • The company's full-year revenue for 2024 was $1.73 billion, which was within the original guidance despite a $60 million FX headwind.
2. Expense Trend:
   • Like revenue, Nu Skin's expenses for Q4 2024 were not provided, but the company reported a decrease in expenses year-over-year.
   • The company's adjusted gross margin for Q4 2024 was 71.4%, down from 72.1% in the prior year.
   • The core Nu Skin Business Gross Margin was 76.6%, down from 77.4% due to geographic revenue shifts.
3. Financial Performance:
   • Nu Skin's adjusted earnings per share (EPS) for Q4 2024 were $0.38, surpassing guidance and slightly ahead of the prior year's $0.37.
   • The company's debt reduction in 2024 was $110 million, funded through cash from operations.
   • Nu Skin's free cash flow was $70 million, a $10 million increase over the prior year.
   • The company returned $12 million to shareholders through dividends.
4. Segment Performance:
   • Nu Skin's Rhyz segment showed strong performance, achieving 28% year-on-year growth in Q4.
   • The Mavely transaction, which involved selling a subsidiary for $250 million, added approximately $200 million in cash to the balance sheet.

In conclusion, Nu Skin's revenue and expenses in Q4 2024 reflected a strategic shift in focus towards core business strengthening and innovation, despite short-term challenges posed by foreign currency impacts and regional market shifts. The company's financial performance indicators, such as EPS and gross margin, showed resilience and improvement, underscored by strong segmental growth and successful corporate transactions.